- Conditions
- Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements
- Interventions
- Futibatinib, Cisplatin, Gemcitabine
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- Duarte, California • Louisville, Kentucky • Albuquerque, New Mexico + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 1,628
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Leukemia
- Interventions
- Gemcitabine Hydrochloride, Mitoxantrone Hydrochloride
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Cleveland, Ohio
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- fluorouracil, gemcitabine hydrochloride, oxaliplatin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 2
- States / cities
- New York, New York • The Bronx, New York
- Conditions
- Solid Tumors
- Interventions
- SU011248; Gemcitabine
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- TNBC - Triple-Negative Breast Cancer, Breast Cancer
- Interventions
- Trilaciclib, Placebo, Gemcitabine, Carboplatin
- Drug
- Lead sponsor
- G1 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more
- Conditions
- Head and Neck Cancer
- Interventions
- gemcitabine, paclitaxel
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 123
- States / cities
- Anniston, Alabama • Mobile, Alabama • Aurora, Colorado + 81 more
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
- Interventions
- Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, Carboplatin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 68 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- gemcitabine hydrochloride, alvocidib, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
- Interventions
- E-EDV-D682, EDV-GC, Gemcitabine, Nab paclitaxel.
- Drug
- Lead sponsor
- Engeneic Pty Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- El Segundo, California • Summit, New Jersey • New York, New York + 1 more
- Conditions
- Malignant Neoplasm, Solid Tumors
- Interventions
- Chloroquine, Carboplatin, Gemcitabine
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer, KRAS P.G12C
- Interventions
- Sotorasib, Liposomal Irinotecan (nal-IRI), 5 Fluorouracil (5FU), Leucovorin (LV), Gemcitabine (GEM), Nab paclitaxel
- Drug
- Lead sponsor
- Devalingam Mahalingam
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Urothelial Cancer, Bladder Cancer
- Interventions
- Neoadjuvant Cisplatin and Gemcitabine
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Ann Arbor, Michigan • Rochester, New York • Portland, Oregon
- Conditions
- Pancreatic Cancer
- Interventions
- genistein, erlotinib hydrochloride, gemcitabine hydrochloride
- Dietary Supplement · Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 21 Years to 120 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Houston, Texas
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Atezolizumab, Carboplatin, Cisplatin, Gemcitabine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 28
- States / cities
- Encinitas, California • Greenbrae, California • La Jolla, California + 25 more
- Conditions
- Advanced Pancreatic Cancer
- Interventions
- AB680, Zimberelimab, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 9
- States / cities
- Santa Monica, California • St Louis, Missouri • New York, New York + 5 more
- Conditions
- Lymphoma
- Interventions
- Gemcitabine, Pemetrexed
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Selinexor, Rituximab, Bendamustine, Polatuzumab Vedotin, Ibrutinib, Lenalidomide, Tafasitamab, Venetoclax, Gemcitabine, Oxaliplatin
- Drug
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • Encinitas, California • La Jolla, California + 15 more
- Conditions
- Soft Tissue Sarcoma
- Interventions
- pegylated arginine deiminase, Gemcitabine, Docetaxel, Tumor biopsy, Research blood draw
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Santa Monica, California • St Louis, Missouri + 1 more
- Conditions
- Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
- Interventions
- Anvumetostat, Gemcitabine, Nab-paclitaxel, Modified FOLFIRINOX, RMC-6236
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 29
- States / cities
- Bakersfield, California • Duarte, California • La Jolla, California + 24 more
- Conditions
- Locally Advanced / Metastatic Solid Tumors
- Interventions
- CR-001, Paclitaxel, trifluridine and tipiracil, Pemetrexed, Carboplatin, Oxaliplatin, Gemcitabin, Cisplatin, Capecitabine, FOLFOX
- Drug
- Lead sponsor
- Crescent Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 12 more
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- Greg Durm, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more
- Conditions
- Pancreatic Cancer
- Interventions
- Vatalanib, Gemcitabine
- Drug
- Lead sponsor
- George Albert Fisher
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Stage III Intrahepatic Cholangiocarcinoma, Stage IVA Intrahepatic Cholangiocarcinoma
- Interventions
- Image Guided Radiation Therapy
- Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 25 more
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms
- Interventions
- Gemcitabine Delivered by Transarterial Microperfusion
- Combination Product
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Burlington, Vermont